SCHEMBL4170965

SCHEMBL4170965

Cc1ccc2c(c1)C1(NC(=O)NC1=O)C(=O)N2Cc1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
KMT2A Q03164 2/20 0.42
ALOX12 P18054 1/20 0.42
MAPT P10636 4/20 0.40
HTT P42858 3/20 0.40
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
ADAMTS5 Q9UNA0 2/20 0.39
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
GAA P10253 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164805 0.89 ADAMTS5 (0.46) RAB9AKMT2AMAPTHTTALDH1A1
SCHEMBL4164794 0.89 RAB9A (0.46) RAB9AKMT2AMAPTHTTALDH1A1
SCHEMBL4167707 0.87 RAB9A (0.49) RAB9AKMT2AMAPTHTTALDH1A1
SCHEMBL4258971 0.82 TP53 (0.45) MAPTALDH1A1ADAMTS5SMN1; SMN2PTGDR2
SCHEMBL4162377 0.80 AKR1A1 (0.44) RAB9AKMT2AMAPTALDH1A1NPC1
SCHEMBL4254345 0.77 PTGDR2 (0.42) MAPTPOLBSMN1; SMN2PTGDR2LMNA
SCHEMBL4159534 0.76 ADAMTS5 (0.42) KMT2AMAPTALDH1A1ADAMTS5SMN1; SMN2
SCHEMBL4161684 0.75 L3MBTL1 (0.39) MAPTALDH1A1POLBADAMTS5PTGDR2
SCHEMBL4259885 0.75 ADAMTS5 (0.52) KMT2AMAPTHTTALDH1A1MEN1
SCHEMBL4266332 0.74 ADAMTS5 (0.40) MAPTADAMTS5AKR1A1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US claimed
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 RAB9A 678/4885KMT2A 4449/4885ALOX12 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.